Clinical Trails Post

October 2025 clinical trial highlights

by Pulmonary Fibrosis Foundation
October 15, 2025
Lungs

Clinical trial participants are essential in the quest for new treatments and a cure for pulmonary fibrosis (PF).

Each month, we'll highlight a few of the many trials that are enrolling volunteers. To view more available trials for various forms of interstitial lung disease (ILD), please visit the 🔍 PFF Clinical Trial Finder.


Seeking participants with IPF

WISPer

  • Study ID: NCT06967805
  • Trial Phase: Phase 2a
  • Intervention: Intravenous injection
  • Sponsor: Mediar Therapeutics
  • Study Contact: WISPer@mediartx.com 

Learn more about this study

Learn more about this drug

Seeking participants with IPF

Oral Ifetroban in Patients with IPF

  • Study ID: NCT05571059
  • Trial Phase: Phase 2
  • Intervention: Oral drug
  • Sponsor: Cumberland Pharmaceuticals 
  • Study Contact: Ines Macias-Perez, PhD (615.979.5778; imaciasperez@cumberlandpharma.com); Ingrid Anderson, PhD, CCRP (615.627.4121; ianderson@cumberlandpharma.com) 

Learn more about this study

Learn more about this drug

Seeking participants with SSc-ILD

EFZO-CONNECT

  • Study ID:  NCT05892614
  • Trial Phase: Phase 2
  • Intervention: Intravenous injection
  • Sponsor: aTyr Pharma, Inc.
  • Study Contact: aTyr Pharma Clinical Research (877.215.5731; clinicaltrials@atyrpharma.com)

Learn more about this study

Learn more about this drug 

     

    Resource spotlight: PF Drug Development Pipeline

    The PF Drug Development Pipeline is a helpful resource for individuals interested in learning about the latest in drug development for PF-related conditions.

    View pipeline

     

    Ambassador

    Cheri was enjoying her retirement with days full of laughter, joy, and creativity, when a routine exam revealed she had idiopathic pulmonary fibrosis (IPF). This diagnosis turned her world upside down, and she initially struggled to understand and accept the seriousness of her condition.

    To navigate this unexpected journey, Cheri sought support from a counselor and found herself expert care from a compassionate medical team at a PFF Care Center site. Today, she embraces life while adapting to IPF, participates in clinical trials, raises awareness as a PFF Ambassador, and advocates for research by speaking with her congressional representatives as a PFF Advocate.

    The PFF Care Center Network provides high-quality care, engages in ILD research, and works to educate local communities about PF. To learn more about the Network and find yourself expert medical care, visit our PFF Care Center Network webpage.

    FDA approves Nerandomilast (Jascayd) for IPF

    In October 2025, Boehringer Ingelheim announced that the FDA approved nerandomilast (Jascayd) for the treatment of IPF. This is the first new treatment for IPF in over a decade. Nerandomilast is an oral phosphodiesterase 4B (PDE4B) inhibitor that significantly slowed the rate of lung function decline in the Phase III FIBRONEER-IPF clinical trial. The FDA is expecting to review data from the positive Phase 3 FIBRONEER-ILD trial for PPF in the upcoming months.

    This approval is a significant milestone for patients, caregivers, and clinicians, offering new treatment options to target the unmet needs for patients living with IPF. The impact of IPF remains profound, and the need for additional effective treatments continues.

    Phase 3 IPF study meets its primary endpoint

    In September 2025, United Therapeutics announced positive results of its phase 3 study, TETON-2. The TETON-2 study evaluated the use of inhaled treprostinil (Tyvaso®) and this study showed that people living with IPF who took the drug had better lung function compared to those who were on placebo meeting the study’s primary endpoint. TETON-2 also demonstrated the safety and tolerability of treprostinil.

    A primary endpoint is the measurement that researchers use to determine if a medication or other intervention works as intended. In continuation of TETON-2, United Therapeutics is currently conducting a phase 3 TETON-OLE study in the US, and you can learn more here.

    The TETON-2 study successfully meeting its primary endpoint is a significant accomplishment for the drug development space and PF community. United Therapeutics intends to submit a supplemental New Drug Application to the FDA to expand treprostinil’s approved indications to include IPF.

    You can still register for the largest conference on PF and ILD

    As the PFF celebrates a milestone 25 years of funding groundbreaking research, uniting patients and professionals, and lighting the path toward a cure, it also prepares for its eighth highly anticipated PFF Summit conference. Set to take place in Chicago from November 13 to 15, the Summit underscores the Foundation's enduring legacy and future ambitions.

    At the PFF Summit, you'll dive into the latest updates on research with activities such as the scientific poster presentations and sessions like "Research in the pipeline: What might the next 25 years hold?" In addition, the popular Clinical Trial Innovation Series makes a return to the Summit. In this two-part series, groundbreaking research takes the stage as trial sponsors report on the latest findings in clinical trials.

    Register and learn more

    If you have any questions or comments about this newsletter, please email partnerships@pulmonaryfibrosis.org.